Mirae Asset Global Investments Co. Ltd. Has $758,000 Stake in AtriCure, Inc. (NASDAQ:ATRC)

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,237 shares of the medical device company’s stock after acquiring an additional 484 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in AtriCure were worth $758,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ATRC. SG Americas Securities LLC acquired a new stake in shares of AtriCure during the third quarter worth $603,000. HighMark Wealth Management LLC increased its stake in AtriCure by 175.6% in the 3rd quarter. HighMark Wealth Management LLC now owns 2,825 shares of the medical device company’s stock valued at $124,000 after buying an additional 1,800 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in AtriCure by 17.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 20,936 shares of the medical device company’s stock valued at $917,000 after buying an additional 3,086 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new stake in AtriCure in the 3rd quarter valued at $28,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in AtriCure by 14.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,854 shares of the medical device company’s stock valued at $432,000 after buying an additional 1,238 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Performance

Shares of ATRC stock opened at $23.05 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.66 and a current ratio of 3.57. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -34.92 and a beta of 1.38. AtriCure, Inc. has a 52 week low of $22.27 and a 52 week high of $59.61. The company has a 50-day simple moving average of $30.25 and a 200 day simple moving average of $33.84.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.09) EPS. On average, sell-side analysts predict that AtriCure, Inc. will post -0.71 earnings per share for the current year.

Analysts Set New Price Targets

ATRC has been the topic of several recent research reports. StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Stifel Nicolaus lowered their price objective on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. UBS Group boosted their price objective on shares of AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of AtriCure in a research note on Wednesday, April 10th. Finally, Oppenheimer upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $52.63.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Karl S. Dahlquist sold 8,231 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total transaction of $307,510.16. Following the sale, the insider now directly owns 52,839 shares in the company, valued at $1,974,065.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Karl S. Dahlquist sold 8,231 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $37.36, for a total transaction of $307,510.16. Following the completion of the sale, the insider now directly owns 52,839 shares in the company, valued at approximately $1,974,065.04. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $30.39, for a total transaction of $45,585.00. Following the transaction, the insider now owns 72,784 shares of the company’s stock, valued at $2,211,905.76. The disclosure for this sale can be found here. Insiders sold 13,116 shares of company stock valued at $468,797 in the last quarter. Company insiders own 3.20% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.